Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orphazyme A/S

http://www.orphazyme.com

Latest From Orphazyme A/S

Orphazyme’s Sorry Story Ends In Fire Sale

While Orphazyme's attempts to get approval for arimoclomol failed miserably, new owner KemPharm is confident it can get the oral heat shock protein amplifier across the regulatory finishing line for Niemann-Pick disease type C.

M & A Rare Diseases

Finance Watch: More Job Cuts As Companies Prioritize Cash Conservation

Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US. 

Financing Strategy

Europe's Biotechs In Battle For Survival

Saniona and Bone Therapeutics are the latest companies on the continent to be forced into drastic restructuring, shedding jobs and research projects to preserve rapidly dwindling cash piles.

Financing StartUps and SMEs

Janssen’s Multiple Myeloma Gene Therapy On Track For EU-Wide Approval

The European Medicines Agency’s human medicines committee has recommended five new drugs for use in the EU at its latest monthly meeting.

Approvals Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Orphazyme US, Inc.
UsernamePublicRestriction

Register